Alaunos Therapeutics Inc. (TCRT)
NASDAQ: TCRT
· Real-Time Price · USD
2.27
-0.13 (-5.42%)
At close: Aug 15, 2025, 3:59 PM
2.20
-2.87%
After-hours: Aug 15, 2025, 07:31 PM EDT
Alaunos Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 2K | 4K | n/a | 4K | 1K | 1K | n/a | 4K | n/a | 11K | 2.91M | n/a | n/a | n/a | 398K | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | 1K | 2K | 241K | 1.06M | 1.53M | 696K | 805K | 691K | 685K | 689K | 705K | n/a | 679K | 540K |
Gross Profit | 2K | 4K | n/a | 3K | -1K | -240K | -1.06M | -1.53M | -696K | -794K | 2.22M | -685K | -689K | -705K | 398K | -679K | -540K |
Operating Income | -1.09M | -755K | -1.15M | -1.17M | -1.74M | -3.36M | -8.66M | -7.98M | -9.67M | -8.52M | -8.26M | -9.23M | -9.09M | -11.05M | -22.3M | -22.64M | -21.56M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -1.07M | -742K | -1.13M | -1.13M | -1.68M | -7.84M | -8.48M | -8.77M | -10.05M | -9.16M | -8.85M | -9.93M | -9.79M | -11.79M | -22.73M | -22.67M | -21.55M |
Net Income | -1.07M | -742K | -1.13M | -1.13M | -1.68M | -7.84M | -8.48M | -8.77M | -9.35M | -9.8M | -9.44M | -9.8M | -10.49M | -11.79M | -22.73M | -22.67M | -21.55M |
Selling & General & Admin | 747K | 845K | 1.01M | 990K | 1.61M | 2.19M | 3.58M | 3.04M | 3.17M | 2.92M | 3.28M | 3.43M | 3.5M | 2.09M | 8.17M | 9.07M | 8.23M |
Research & Development | 347K | -86K | 143K | 180K | 126K | 933K | 3.66M | 5.19M | 6.5M | 5.61M | 7.89M | 5.94M | 5.58M | 8.22M | 14.52M | 13.57M | 13.34M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | 188K | 277K | 477K | 250K | 254K | 41K | -20K | -744K | 7K | -31K | 9K |
Operating Expenses | 1.09M | 759K | 1.15M | 1.17M | 1.74M | 3.12M | 7.23M | 8.23M | 9.67M | 8.53M | 11.18M | 9.37M | 9.09M | 10.31M | 22.69M | 22.64M | 21.56M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.07M | 853K | 888K | 841K | 740K | 683K | 743K | 437K | 31K | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | -2K | -241K | n/a | n/a | n/a | -6.79M | n/a | n/a | n/a | -25.47M | n/a | n/a | n/a |
Cost & Expenses | 1.09M | 759K | 1.15M | 1.17M | 1.74M | 3.36M | 7.23M | 8.23M | 9.67M | 8.53M | 11.18M | 9.37M | 9.09M | 10.31M | 22.69M | 22.64M | 21.56M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | -837K | n/a | n/a | -696K | 638K | 587K | -133K | 703K | 723K | n/a | 31K | -9K |
Shares Outstanding (Basic) | 1.6M | 1.6M | 1.6M | 1.6M | 1.6M | 1.6M | 1.6M | 1.6M | 1.6M | 1.49M | 1.43M | 1.43M | 1.43M | 1.43M | 1.43M | 1.43M | 1.43M |
Shares Outstanding (Diluted) | 1.6M | 1.6M | 1.6M | 1.6M | 1.6M | 1.6M | 1.6M | 1.6M | 1.6M | 1.49M | 1.43M | 1.43M | 1.43M | 1.43M | 1.43M | 1.43M | 1.43M |
EPS (Basic) | -0.67 | -0.46 | -0.7 | -0.71 | -1.05 | -4.9 | -5.3 | -5.49 | -5.85 | -6.58 | -6.58 | -6.84 | -7.32 | -8.24 | -15.89 | -15.86 | -15.11 |
EPS (Diluted) | -0.67 | -0.46 | -0.7 | -0.71 | -1.05 | -4.9 | -5.3 | -5.49 | -5.85 | -6.58 | -6.58 | -6.84 | -7.32 | -8.24 | -15.89 | -15.86 | -15.11 |
EBITDA | -1.07M | -742K | -1.13M | -1.13M | -1.68M | -7.6M | -7.41M | -7.01M | -8.5M | -7.47M | -7.32M | -8.51M | -8.42M | -10.35M | -21.62M | -21.99M | -21.01M |
EBIT | -1.07M | -742K | -1.13M | -1.13M | -1.68M | -7.84M | -8.48M | -7.71M | -9.2M | -8.27M | -8.01M | -9.19M | -9.11M | -11.07M | -22.29M | -22.67M | -21.55M |
Depreciation & Amortization | n/a | -1K | 23K | 1K | 2K | 241K | 1.06M | 1.53M | 696K | 805K | 691K | 685K | 689K | 705K | 673K | 679K | 540K |